Literature DB >> 16955304

[Mechanisms of specific immunotherapy].

I Bellinghausen1, J Knop, J Saloga.   

Abstract

Specific immunotherapy (SIT) is a well-established and clinically effective treatment for allergic rhinitis and bronchial asthma. The immunological mechanisms of the subcutaneously applied immunotherapy have been partially elucidated over the past several years but are not completely understood. This report summarizes the immunological and immunoregulatory changes during SIT of wasp venom allergic patients. The induction of IL-10-producing regulatory T cells is described.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16955304     DOI: 10.1007/s00105-006-1200-1

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  30 in total

Review 1.  Dendritic cells as a tool to induce anergic and regulatory T cells.

Authors:  H Jonuleit; E Schmitt; K Steinbrink; A H Enk
Journal:  Trends Immunol       Date:  2001-07       Impact factor: 16.687

2.  Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study).

Authors:  Christian Möller; Sten Dreborg; Hosne A Ferdousi; Susanne Halken; Arne Høst; Lars Jacobsen; Antti Koivikko; Dieter Y Koller; Bodo Niggemann; Lene A Norberg; Radvan Urbanek; Erkka Valovirta; Ulrich Wahn
Journal:  J Allergy Clin Immunol       Date:  2002-02       Impact factor: 10.793

Review 3.  T regulatory cells in allergy: novel concepts in the pathogenesis, prevention, and treatment of allergic diseases.

Authors:  Mübeccel Akdis; Kurt Blaser; Cezmi A Akdis
Journal:  J Allergy Clin Immunol       Date:  2005-10-10       Impact factor: 10.793

Review 4.  The role of interleukin 10 in the regulation of allergic immune responses.

Authors:  I Bellinghausen; J Knop; J Saloga
Journal:  Int Arch Allergy Immunol       Date:  2001-10       Impact factor: 2.749

5.  CD4(+) and CD8(+) anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity.

Authors:  Kerstin Steinbrink; Edith Graulich; Sebastian Kubsch; Jürgen Knop; Alexander H Enk
Journal:  Blood       Date:  2002-04-01       Impact factor: 22.113

6.  Regulatory activity of human CD4 CD25 T cells depends on allergen concentration, type of allergen and atopy status of the donor.

Authors:  Iris Bellinghausen; Bettina König; Ingo Böttcher; Jürgen Knop; Joachim Saloga
Journal:  Immunology       Date:  2005-09       Impact factor: 7.397

7.  Importance of the inducible costimulator molecule for the induction of allergic immune responses and its decreased expression on T helper cells after venom immunotherapy.

Authors:  Iris Bellinghausen; Bettina Klostermann; Ingo Böttcher; Jürgen Knop; Joachim Saloga
Journal:  Immunology       Date:  2004-05       Impact factor: 7.397

8.  Role of interleukin 10 in specific immunotherapy.

Authors:  C A Akdis; T Blesken; M Akdis; B Wüthrich; K Blaser
Journal:  J Clin Invest       Date:  1998-07-01       Impact factor: 14.808

9.  Decreased release of histamine and sulfidoleukotrienes by human peripheral blood leukocytes after wasp venom immunotherapy is partially due to induction of IL-10 and IFN-gamma production of T cells.

Authors:  M Pierkes; I Bellinghausen; T Hultsch; G Metz; J Knop; J Saloga
Journal:  J Allergy Clin Immunol       Date:  1999-02       Impact factor: 10.793

10.  Interleukin 4 production by CD4+ T cells from allergic individuals is modulated by antigen concentration and antigen-presenting cell type.

Authors:  H Secrist; R H DeKruyff; D T Umetsu
Journal:  J Exp Med       Date:  1995-03-01       Impact factor: 14.307

View more
  2 in total

Review 1.  [In vitro diagnosis and monitoring of Hymenoptera venom hyposensitization].

Authors:  M M Neis; G Wurpts; L Wilbers; H F Merk
Journal:  Hautarzt       Date:  2011-09       Impact factor: 0.751

2.  Potential therapy of Fc-antigen combination-encoding DNA vaccination in mouse allergic airway inflammation.

Authors:  Y Wang; G Qian; G Wang; X Cheng; C Bai; X Wang
Journal:  Clin Exp Immunol       Date:  2008-08-22       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.